NCT06998004

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults

A Phase I, Randomized, Double-blind, Multi-centre, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of AstriVax' Investigational Vaccine for the Prevention of Yellow Fever (AVX70120), and of AstriVax' Investigational Vaccine for the Prevention of Rabies (AVX70481), in Healthy Adults Aged 18 to 40 Years

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: AstriVax Therapeutics · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.

Conditions

• Yellow Fever
• Rabies

Interventions

Type	Name	Description
BIOLOGICAL	AVX70120 low dose level	Low dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
BIOLOGICAL	AVX70120 middle dose level	Middle dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
BIOLOGICAL	AVX70120 high dose level	High dose level of AVX70120, AstriVax' investigational vaccine for the prevention of yellow fever
BIOLOGICAL	AVX70481 low dose level	Low dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
BIOLOGICAL	AVX70481 middle dose level	Middle dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
BIOLOGICAL	AVX70481 high dose level	High dose level of AVX70481, AstriVax' investigational vaccine for the prevention of rabies
OTHER	Placebo	Placebo

Timeline

• Start date: 2024-06-16
• Primary completion: 2026-03-31
• Completion: 2026-03-31
• First posted: 2025-05-31
• Last updated: 2025-05-31

Locations

2 sites across 1 country: Belgium